These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2144390)

  • 1. Cost of plasma-derived hepatitis B vaccine production.
    Mahoney RT
    Vaccine; 1990 Aug; 8(4):397-401. PubMed ID: 2144390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost analysis of producing vaccines in developing countries.
    Munira SL; Hendriks JT; Atmosukarto II; Friede MH; Carter LM; Butler JRG; Clements ACA
    Vaccine; 2019 Feb; 37(9):1245-1251. PubMed ID: 30651198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Production of a vaccine against hepatitis B in Africa: the problems and prospects].
    Nasidi A; Herry TO
    Vopr Virusol; 1986; 31(5):591-4. PubMed ID: 3798908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.
    Kane MA; Hadler SC; Lee L; Shapiro CN; Cui F; Wang X; Kumar R
    Vaccine; 2013 Dec; 31 Suppl 9():J15-20. PubMed ID: 24331015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa.
    Edmunds W; Dejene A; Mekonnen Y; Haile M; Alemnu W; Nokes D
    Health Policy Plan; 2000 Dec; 15(4):408-16. PubMed ID: 11124244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness.
    Stephenne J
    Vaccine; 1988 Aug; 6(4):299-303. PubMed ID: 2973187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing the acceptance of hepatitis B vaccine by students in health disciplines in Ottawa.
    Pennie RA; O'Connor AM; Garvock MJ; Drake ER
    Can J Public Health; 1991; 82(1):12-5. PubMed ID: 1826226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit analysis of hepatitis-B vaccination. A computerized decision model for Spain.
    Jönsson B; Horisberger B; Bruguera M; Matter L
    Int J Technol Assess Health Care; 1991; 7(3):379-402. PubMed ID: 1834602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B vaccine for medical students.
    Chodash HB
    IMJ Ill Med J; 1986 Mar; 169(3):145-6. PubMed ID: 2870035
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil.
    Mahoney RT; Francis DP; Frazatti-Gallina NM; Precioso AR; Raw I; Watler P; Whitehead P; Whitehead SS
    Vaccine; 2012 Jul; 30(32):4892-6. PubMed ID: 22406455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose intradermal vaccination of medical and dental students.
    Wilkins TD; Cossart YE
    Med J Aust; 1990 Feb; 152(3):140-3. PubMed ID: 2137192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustainable introduction of affordable new vaccines: the targeting strategy.
    Batson A
    Vaccine; 1998 Nov; 16 Suppl():S93-8. PubMed ID: 9915047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very-low-dose hepatitis B vaccine in newborn infants: an economic option for control in endemic areas.
    Moyes CD; Milne A; Dimitrakakis M; Goldwater PN; Pearce N
    Lancet; 1987 Jan; 1(8523):29-31. PubMed ID: 2879101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of low-dose intradermal recombinant DNA hepatitis B vaccine.
    Parish DC; Muecke HW; Joiner TA; Pope WT; Hadler SC
    South Med J; 1991 Apr; 84(4):426-30. PubMed ID: 1826567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B Vaccine in national immunization schedule: a preventive step in India.
    Verma R; Khanna P; Prinja S; Rajput M; Chawla S; Bairwa M
    Hum Vaccin; 2011 Dec; 7(12):1387-8. PubMed ID: 22134433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B: global importance and need for control.
    Maynard JE
    Vaccine; 1990 Mar; 8 Suppl():S18-20; discussion S21-3. PubMed ID: 2139281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A cost-effectiveness analysis of vaccination against the hepatitis B virus].
    Antoñanzas F; Forcén T; Garuz R
    Med Clin (Barc); 1992 Jun; 99(2):41-6. PubMed ID: 1630178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of intradermal hepatitis B immunization of hospital staff.
    McKee CM; Duke P; McEvoy MB; Kelsey MC
    Int J STD AIDS; 1990 Jan; 1(1):32-4. PubMed ID: 2151564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of hepatitis B vaccination into rural African primary health care programmes.
    Schoub BD; Johnson S; McAnerney JM; Blackburn N; Kew MC; McCutcheon JP; Carlier ND
    BMJ; 1991 Feb; 302(6772):313-6. PubMed ID: 1825799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.